Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    Genomics group gets $75m capital injection

    By HE WEI in Shanghai | China Daily | Updated: 2017-05-03 08:10
    Share
    Share - WeChat

    WuXi NextCODE, a contract genomics company headquartered in Shanghai, announced on Tuesday that it received a $75 million capital injection, as China targets precision medicine using gene sequencing as a new focus for improving health and medical standards.

    The fresh financing is being led by Yunfeng Capital, a fund backed by billionaire Jack Ma, chairman of Alibaba Group Holding Ltd, and Singaporean investment firm Temasek Holdings Pte, WuXi NextCODE said in a statement.

    The company said it will use the proceeds from this round of financing to advance the commercialization of its consumer solutions for the China market, strengthen its global leadership position in informatics, and expand its capabilities in artificial intelligence and deep learning.

    "Genomics is at the crossroads where data and biology meet," said Li Ge, chairman of WuXi NextCODE and its parent WuXi AppTec Inc.

    "Through its comprehensive capabilities for digitizing, managing and analyzing genome data, WuXi NextCODE is positioned to build an open access and capability platform that enables any organization or individual to benefit from genomic big data," he said.

    WuXi NextCODE was formed in 2015 after Shanghai-based contract research giant WuXi AppTec acquired genomic analysis firm NextCode Health, a spinoff from Reykjavik, Iceland-based Decode Genetics.

    With offices in Shanghai, Reykjavik and Cambridge in the United States, the company provides capabilities for generating, organizing, mining and applying genomic data.

    Ideally, gene sequencing can enable doctors to use a person's genome and physiology to determine the best treatments for a disease.

    To make better use of the pool of information, WuXi NextCODE announced a partnership last year with Huawei Technologies Co, China's largest telecommunications equipment maker, to enable different institutions and researchers to store their data.

    Included in the 13th Five-Year Plan (2016-20), precision medicine is predicted to be the next big thing as China moves to upgrade its healthcare landscape. By 2030, the industry expects investments to soar to approximately 60 billion yuan ($8.7 billion), according to US-based market research firm BCC Research.

    Gene research is not only an effective way to prevent birth defects and discover genetic diseases in their early stages. It can also provide drugs and treatment plans tailored to a person's unique genetic code and environmental exposure, said Xu Ruiqi, general-manager of BGI's Shanghai branch, a world-leading genome sequencer.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    日本久久久精品中文字幕| 蜜桃成人无码区免费视频网站| 日韩AV片无码一区二区不卡电影 | 无码中文人妻视频2019| 最近2022中文字幕免费视频| 国产精品无码免费专区午夜| 中国无码人妻丰满熟妇啪啪软件 | 狠狠精品干练久久久无码中文字幕 | 国产成人亚洲综合无码| 中文字字幕在线中文无码| 最近2019好看的中文字幕| 中国少妇无码专区| 精品亚洲成α人无码成α在线观看| 亚洲AV无码国产丝袜在线观看| 暖暖免费在线中文日本| 亚洲av无码成人精品区在线播放 | 精品久久久久久久无码| 在线观看片免费人成视频无码| 色婷婷综合久久久久中文字幕| 免费无码中文字幕A级毛片| 人妻一区二区三区无码精品一区 | 精品人妻系列无码人妻免费视频| 人禽无码视频在线观看| 亚洲AV无码成人精品区在线观看 | 亚洲AV区无码字幕中文色| 日韩人妻无码一区二区三区综合部| 最近2019年免费中文字幕高清| 免费人妻无码不卡中文字幕系| 亚洲AV中文无码字幕色三| 久久亚洲中文字幕精品一区| 中文字幕无码一区二区三区本日| 国产成人无码精品久久久免费| 国产高新无码在线观看| 日韩乱码人妻无码中文视频| 久久久无码精品午夜| 无码专区一va亚洲v专区在线 | 亚洲无av在线中文字幕| 亚洲中文字幕无码永久在线| 久久精品aⅴ无码中文字字幕不卡| 中文字幕在线亚洲精品| 色综合中文综合网|